Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2021, with a specific reporting date of September 3, 2021. The document serves as a transaction notification regarding insider trading activities under the UK Market Abuse Regulation, rather than a financial performance report.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the transaction price for ordinary shares.
- Share Price: £14.62 per ordinary share.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details two specific share award transactions executed on August 31, 2021, under the Company's 2015 Share Value Plan.
- Transaction 1: Award of 10,050 shares to Mrs. V A Whyte (SVP & Company Secretary).
- Transaction 2: Award of 6,330 shares to Mr. D Jackson (Person Closely Associated with Ms. S Jackson, SVP, Global Communications and CEO Office).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of share awards to Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them.
Investor Verification Checklist
- Verify the total volume of shares awarded (16,380 shares) against the company's broader equity compensation plan disclosures.
- Confirm the share price of £14.62 aligns with the market price on the transaction date of August 31, 2021.
- Review the 2015 Share Value Plan terms to understand the vesting conditions associated with these awards.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.